Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR1 | P21462 | 1/20 | 0.51 |
| ▸ | FPR2 | P25090 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 2/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | EED | O75530 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL3552212 | 1.00 | FPR1 (0.51) | FPR1FPR2NAMPTMCHR1CNR1 | |
| Trifluoroacetic Acid SCHEMBL3552688 | 0.92 | FPR1 (0.54) | FPR1FPR2NAMPTMCHR1CNR1 | |
| Bicarbonate SCHEMBL5240144 | 0.86 | FPR1 (0.50) | FPR1FPR2NAMPTMCHR1CNR1 | |
| Bicarbonate SCHEMBL3556227 | 0.82 | CCNC (0.43) | FPR1FPR2EEDHRH3CCNC | |
| SCHEMBL5203906 | 0.82 | CASP6 (0.50) | FPR1FPR2NAMPTMCHR1SYK | |
| SCHEMBL3551660 | 0.82 | CASP6 (0.50) | FPR1FPR2NAMPTMCHR1SYK | |
| SCHEMBL3551801 | 0.82 | CASP6 (0.50) | FPR1FPR2NAMPTMCHR1SYK | |
| Hydrochloric Acid SCHEMBL5406630 | 0.80 | FPR1 (0.49) | FPR1FPR2NAMPTMCHR1SYK | |
| Hydrochloric Acid SCHEMBL5383077 | 0.80 | FPR1 (0.49) | FPR1FPR2NAMPTMCHR1SYK | |
| SCHEMBL27258755 | 0.80 | DRD2 (0.59) | NAMPTMCHR1CNR1DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655652-B2 | 2-{4-[4-(2-hydroxyacetyl)piperazin-1-yl]anilino}-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-5-fluoropyrimidine hydrochloride; cell cycle inhibitory; rheumatoid arthritis | ASTRAZENECA AB (SE) | 2010-02-02 | — | — | US | disclosed |
| US-20070161615-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | US | disclosed |
| EP-1748999-A1 | IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005075461-A1 | IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161615-A1 | Chemical compounds | MKI67, PCNA, CCNI | FPR1 3252/4885FPR2 4303/4885NAMPT 2220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.